Karyopharm Therapeutics Inc.(NASQAD:KPTI) is a publicly traded, clinical-stage pharmaceutical company headquarted in Newton, MA, with offices also in Germany. Focused on discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, the firm is developing novel, small molecule Selective Inhibitor of Nuclear Export, or SINE, compounds that inhibit the nuclear export protein XPO1. These SINE compounds represent a new class of drug candidates with a novel mechanism of action that have the potential to treat a variety of diseases in areas of unmet medical need. The firm has several durgs in the pipeline including, selinexor (KPT-330), an XPO1 inhibitor being evaluated in multiple late stage clinical trials in patients with relapsed and/or refractory hematological and solid tumor malignancies. In January 018, Karyopharm Therapeutics' SINE compound KPT-350 was acquired by Biogen Idec for $10M.
